Page last updated: 2024-11-13

osteum

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23665730
CHEMBL ID3527599
CHEBI ID81860
SCHEMBL ID3582
MeSH IDM0060740

Synonyms (59)

Synonym
oleate, sodium
143-19-1
sodium (9z)-octadec-9-enoate
sodium 9-octadecenoate
sodium 9-octadecenoate, (z)-
oleic acid sodium salt
9-octadecenoic acid (z)-, sodium salt
einecs 205-591-0
ai3-19806
9-octadecenoic acid, sodium salt, (z)-
olate flakes
9-octadecenoic acid (9z)-, sodium salt
osteum
eunatrol
hsdb 758
9-octadecenoic acid, sodium salt
sodium oleate
ccris 1964
oleic acid, sodium salt
sodium oleate, >=99%
sodium oleate, >=95% (capillary gc)
O0057
399sl044hn ,
unii-399sl044hn
9-octadecenoic acid (9z)-, sodium salt (1:1)
C18601
AKOS017345104
sodium oleate [mart.]
e-470(ii)oleic acid, sodium salt
ins-470(ii)oleic acid, sodium salt
oleate sodium
sodium oleate [hsdb]
sodium oleate [who-dd]
oleic acid sodium salt [mi]
ins no.470(ii)oleic acid, sodium salt
sodium oleate [inci]
oleate sodium [green book]
SCHEMBL3582
CHEBI:81860 ,
BCKXLBQYZLBQEK-KVVVOXFISA-M
sodium (z)-octadec-9-enoate
sodiumoleate
CHEMBL3527599
DTXSID7021077 ,
mfcd00004438
cis-9-octadecenoic acid sodium salt
sodium oleate, >=98.5% (gc)
oleic acidsodium salt
16558-02-4
sodium;(z)-octadec-9-enoate
AS-10421
Q17397737
A885003
CS-0107318
HY-N1446B
oleic acid sodium;9-cis-octadecenoic acid sodium;9z-octadecenoic acid sodium
dtxcid001077
sodium oleate (mart.)
c18h33nao2

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"To improve the limited oral bioavailability of sulpiride, a dosage form containing sodium oleate as an absorption enhancer was developed and evaluated using gastric-emptying-controlled rabbits in a cross-over manner."( Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Iseki, K; Kohri, N; Miyazaki, K; Naasani, I, 1995
)
0.29
" LPs also decreased oleate-induced microsomal triglyceride transfer protein (MTTP) mRNA expression and cellular total cholesterol, suggesting that lipid bioavailability and lipidation of lipoprotein are likely involved in the decreased secretion of apo-B."( Lignophenols decrease oleate-induced apolipoprotein-B secretion in HepG2 cells.
Fujita, S; Funaoka, M; Mikame, K; Mukai, Y; Norikura, T; Sato, S, 2010
)
0.36
"2-fold improved oral bioavailability of leuprolide oleate SMEDDS compared to a leuprolide acetate control solution."( In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Bernkop-Schnürch, A; Hauptstein, S; Hintzen, F; Laffleur, F; Müller, C; Perera, G, 2014
)
0.4
" This paper aimed to explore the performance of polymeric mixed micelles on solubilization, stabilization and bioavailability enhancement with stiripentol as model drug."( Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug.
Wang, H; Wu, B; Zhang, T; Zhang, X; Zhou, X, 2014
)
0.4
"Oral bioavailability of flavonoids (and many phenolic drugs) is severely limited by extensive first-pass glucuronidation."( Sodium Oleate-Based Nanoemulsion Enhances Oral Absorption of Chrysin through Inhibition of UGT-Mediated Metabolism.
Dong, D; Li, Z; Quan, E; Wu, B; Xie, Q; Yuan, X, 2017
)
0.46
"The formulation of the antituberculosis drug rifampicin embedded into 20-30 nm nanoparticles from soy phosphatidylcholine and sodium oleate, is characterized by greater bioavailability as compared with free drug substance."( [Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate].
Ipatova, OM; Medvedeva, NV; Prozorovskiy, VN; Sanzhakov, MA; Tikhonova, EG; Torkhovskaya, TI; Zakharova, TS, 2018
)
0.48
" Overall, results revealed the capability of ufosomes in improving the skin bioavailability of clotrimazole."( Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies.
Bolla, PK; Deaguero, I; Meraz, CA; Renukuntla, J; Rodriguez, VA; Singh, M; Yellepeddi, VK, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The pancreatic bicarbonate and volume outputs correlated with the dosage of HCl administered and with the elevations in plasma secretin concentrations."( Characterization of secretin release in response to food and intraduodenal administration of fat and hydrochloric acid.
Draviam, EJ; Gomez, G; Greeley, GH; Hashimoto, T; Hill, FL; Miyashita, T; Singh, P; Thompson, JC; Uchida, T, 1991
)
0.28
" The cholesterol removal and all the agents used induced dose-response decreases in membrane lipid order as measured by fluorescence polarization or ESR."( The effects of membrane lipid order and cholesterol on the internal and external cationic sites of the Na+-K+ pump in erythrocytes.
Bruckdorfer, KR; Chailley, B; Claret, M; Giraud, F, 1981
)
0.26
"To improve the limited oral bioavailability of sulpiride, a dosage form containing sodium oleate as an absorption enhancer was developed and evaluated using gastric-emptying-controlled rabbits in a cross-over manner."( Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Iseki, K; Kohri, N; Miyazaki, K; Naasani, I, 1995
)
0.29
" This information on melatonin absorption behaviors and its modulation by pharmaceutical excipients can be used in further oral dosage formulations to affect circadian rhythm."( New findings on melatonin absorption and alterations by pharmaceutical excipients using the Ussing chamber technique with mounted rat gastrointestinal segments.
Lee, BJ; Tran, HT; Tran, PH, 2009
)
0.35
" It indicates that partially hydrolyzed polyacrylamide (HPAM), NaOL dosage and pH have a multiple effect on the removal efficiency of NaOL."( Removal of sodium oleate from synthetic manganese leaching solution by coagulation-dissolved air flotation.
Wang, S; Xue, J; Zhong, H, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2 Rattus norvegicus (Norway rat)Ki16.70000.00030.30010.8700AID1210879
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
lipid metabolic processArylacetamide deacetylaseHomo sapiens (human)
xenobiotic metabolic processArylacetamide deacetylaseHomo sapiens (human)
positive regulation of triglyceride catabolic processArylacetamide deacetylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
catalytic activityArylacetamide deacetylaseHomo sapiens (human)
triglyceride lipase activityArylacetamide deacetylaseHomo sapiens (human)
protein bindingArylacetamide deacetylaseHomo sapiens (human)
lipase activityArylacetamide deacetylaseHomo sapiens (human)
serine hydrolase activityArylacetamide deacetylaseHomo sapiens (human)
deacetylase activityArylacetamide deacetylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneArylacetamide deacetylaseHomo sapiens (human)
endoplasmic reticulum membraneArylacetamide deacetylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1210879Competitive inhibition of rat recombinant CYP1A2 expressed in Escherichia coli assessed as inhibition of PHEN O-deethylation by dixon plot analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (178)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (28.65)18.7374
1990's35 (19.66)18.2507
2000's28 (15.73)29.6817
2010's52 (29.21)24.3611
2020's12 (6.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.47 (24.57)
Research Supply Index5.22 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index76.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.55%)5.53%
Reviews2 (1.09%)6.00%
Case Studies1 (0.55%)4.05%
Observational0 (0.00%)0.25%
Other179 (97.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]